WuXi Biologics (Cayman) (FRA:1FW2) Change In Receivables : €0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is WuXi Biologics (Cayman) Change In Receivables?

WuXi Biologics (Cayman)'s change in receivables for the quarter that ended in Dec. 2023 was €0 Mil. It means WuXi Biologics (Cayman)'s Accounts Receivable stayed the same from Jun. 2023 to Dec. 2023 .

WuXi Biologics (Cayman)'s change in receivables for the fiscal year that ended in Dec. 2023 was €-111 Mil. It means WuXi Biologics (Cayman)'s Accounts Receivable increased by €111 Mil from Dec. 2022 to Dec. 2023 .

WuXi Biologics (Cayman)'s Accounts Receivable for the quarter that ended in Dec. 2023 was €726 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. WuXi Biologics (Cayman)'s Days Sales Outstanding for the six months ended in Dec. 2023 was 120.79.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. WuXi Biologics (Cayman)'s liquidation value for the six months ended in Dec. 2023 was €489 Mil.

WuXi Biologics (Cayman) Change In Receivables Historical Data

The historical data trend for WuXi Biologics (Cayman)'s Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi Biologics (Cayman) Change In Receivables Chart

WuXi Biologics (Cayman) Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-69.35

-175.18

-276.41

-215.88

-111.01

WuXi Biologics (Cayman) Semi-Annual Data
	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Receivables	Get a 7-Day Free Trial													-	-	-	-	-

WuXi Biologics (Cayman) Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0 Mil.

WuXi Biologics (Cayman) (FRA:1FW2) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

WuXi Biologics (Cayman)'s Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	726.083	/	1097.057	*	91
=	120.79

2. In Ben Graham's calculation of liquidation value, WuXi Biologics (Cayman)'s accounts receivable are only considered to be worth 75% of book value:

WuXi Biologics (Cayman)'s liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1443.97	-	1612.776	+	0.75 * 726.083	+	0.5 * 226.771
=	489

WuXi Biologics (Cayman) Change In Receivables Related Terms

Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

WuXi Biologics (Cayman) (FRA:1FW2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (FRA:1FW2) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

WXIBF:USA WXXWY:USA 2269:Mexico 02269:Hong Kong 1FW1:Germany

Address

No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092

Website

https://www.wuxibiologics.com

WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 15 billion. North American represented 55.6% of total revenue in 2022. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.

WuXi Biologics (Cayman) (FRA:1FW2) Headlines

No Headlines